Close Menu

NYGC

The company is commercializing a genome-wide sequencing method called MRDetect, developed by researchers at the New York Genome Center and Weill Cornell Medicine. 

The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.

While the New York Genome Center says whole-genome cancer sequencing is the future, companies already offering such tests are struggling to get paid.